Aim: This study used proton magnetic resonance spectroscopy ( 1 H MRS) to measure in vivo brain glutathione (GSH) in adolescents with major depressive disorder (MDD), and explored the relationship between GSH and illness severity and chronicity. Secondarily, associations between GSH and anhedonia, a key symptom of MDD in adolescents, were investigated. Methods: Occipital cortex GSH levels were obtained in 19 psychotropic medication-free adolescents with MDD (ages 12-21) and compared to those in eight healthy control adolescents. Correlations between GSH levels and anhedonia severity were examined both in the full participant sample and within the MDD group. Within the MDD group, correlations between GSH levels and illness severity and chronicity were assessed. Results: Occipital GSH levels were lower in adolescents with MDD compared to controls, but did not correlate with anhedonia (either within the MDD group or the full sample), MDD severity, or onset. There were also no group differences in levels of total choline, creatine, and N-acetylaspartate -all neurometabolites that were simultaneously detected with 1 H MRS. Conclusions: Although preliminary, findings add new data to support the role of oxidative stress in MDD and suggest that lower GSH may be a potential marker of MDD early on in the course of illness.
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Introduction
Major depressive disorder (MDD) is consistently ranked as one of the most common psychiatric conditions among adolescents in the U.S. (Copeland et al., 2011; Kessler et al., 2012; Merikangas et al., 2010) and is accompanied by substantial psychosocial impairment (Asarnow et al., 2005; Jaycox et al., 2009) . Additionally, adolescent MDD is associated with high risk for suicide (Asarnow et al., 2008) , the second leading cause of death in this age group (Heron, 2016) . Despite this clear public health concern, the neurobiological underpinnings and mechanisms of MDD remain poorly understood. Recent data point to the potential role of inflammation and oxidative stress, two closely related events, in the pathophysiology of depression (Gardner and Boles, 2011; JimenezFernandez et al., 2015) .
Inflammation is known to increase the production of reactive oxygen and nitrogen species (ROS/RNS). These free radicals can overwhelm cellular antioxidant capacity, leading to oxidative stress, the consequences of which can include mitochondrial dysfunction, further ROS/RNS production, and cell death. Neurons are especially vulnerable to oxidative stress given their high oxygen utilization/metabolism and relatively low levels of antioxidant compounds and enzymes, compared to other tissues (Mytilineou et al., 2002) . Indeed, oxidative stress has been implicated in the pathogenesis of most major neurological/neurodegenerative (e.g., Alzheimer's and Parkinson's diseases) and neuropsychiatric disorders (Bains and Shaw, 1997; Mahadik and Mukherjee, 1996; Mytilineou et al., 2002; Ng et al., 2008) , including adult MDD (Behr et al., 2012; Bilici et al., 2001; Cumurcu et al., 2009; Gibson et al., 2012; Kodydkova et al., 2009) . Glutathione (GSH), a tripeptide thiol and the primary living tissue antioxidant, protects cells and their components against oxidative stress to ensure their normal functioning and replication (Bains and Shaw, 1997; Dringen, 2000) . GSH is therefore a sensitive and reliably endogenous marker of oxidative stress.
Only a few studies to date have investigated GSH abnormalities in MDD. A postmortem study showed lower GSH levels in the prefrontal cortices of patients with MDD, bipolar disorder, and schizophrenia relative to those of controls (Gawryluk et al., 2011) . Other studies examining GSH concentrations in blood serum and plasma have also
